Mycobutin (Rifabutin)

Mycobutin is a rifamycin antibiotic used in several mycobacterial disease contexts.

• Mycobacterium avium complex (MAC) infection: reduces bacterial burden and improves clinical outcomes.
• Prevention of MAC disease in HIV‑positive patients: lowers the risk of disseminated infection.
• Tuberculosis (as part of combination therapy): contributes to bacterial eradication when used with other antitubercular agents.

• Rifabutin inhibits the bacterial DNA‑dependent RNA polymerase by binding to the β‑subunit of the enzyme. This blockade prevents transcription of essential RNA, thereby suppressing protein synthesis and leading to bacterial cell death. The drug’s activity is concentration‑dependent and is most effective against intracellular mycobacteria, including Mycobacterium avium complex and Mycobacterium tuberculosis.

Adverse reactions may occur with rifabutin therapy and are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Rash: erythematous skin eruptions.
• Elevated liver enzymes: transient hepatic enzyme rise.
• Flu‑like symptoms: fever, chills, and myalgia.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury requiring monitoring.
• Neutropenia: marked reduction in neutrophil count.
• Hypersensitivity reactions: including Stevens‑Johnson syndrome.
• Visual disturbances: rare optic neuritis.
• Hemolytic anemia: especially in patients with G6PD deficiency.

Patients should be evaluated for specific risk factors before initiating therapy.

• Liver function monitoring: assess baseline enzymes and repeat during treatment.
• Renal function assessment: adjust use in severe impairment.
• Concomitant drug review: avoid agents that strongly induce CYP3A4.
• Hypersensitivity screening: discontinue if allergic reaction occurs.
• Pregnancy and breastfeeding: use only if benefits outweigh potential risks.
• Store at ambient temperature: keep in original container, protect from moisture and heat.

Rifabutin interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce rifabutin exposure.
• Protease inhibitors (e.g., ritonavir): increase rifabutin levels, risk of toxicity.

Moderate Interactions (Monitor Closely)

• Antiretroviral agents (e.g., efavirenz): may alter plasma concentrations.
• Macrolide antibiotics (e.g., azithromycin): potential additive hepatotoxicity.
• Warfarin: enhanced anticoagulant effect, monitor INR.
• Oral contraceptives: reduced efficacy, advise alternative contraception.